S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
Log in

Therapeutics Acquisition Stock Forecast, Price & News

-0.68 (-4.86 %)
(As of 01/27/2021 12:00 AM ET)
Today's Range
Now: $13.30
50-Day Range
MA: $14.08
52-Week Range
Now: $13.30
Volume30,585 shs
Average Volume14,705 shs
Market Capitalization$186.75 million
P/E RatioN/A
Dividend YieldN/A
Therapeutics Acquisition Corp., doing business as Research Alliance Corp. I, intends to effect a merger, capital stock exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the healthcare industry in the United States. The company was founded in 2020 and is based in Boston, Massachusetts.


Overall MarketRank

0.33 out of 5 stars

Unclassified Sector

67th out of 247 stocks

Holding & Other Investment Offices Industry

66th out of 204 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Holding & other investment offices
Current SymbolNASDAQ:RACA
Phone617 778 2500
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$186.75 million
Next Earnings DateN/A
OptionableNot Optionable
-0.68 (-4.86 %)
(As of 01/27/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RACA News and Ratings via Email

Sign-up to receive the latest news and ratings for RACA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Therapeutics Acquisition (NASDAQ:RACA) Frequently Asked Questions

What stocks does MarketBeat like better than Therapeutics Acquisition?

Wall Street analysts have given Therapeutics Acquisition a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Therapeutics Acquisition wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Therapeutics Acquisition's key competitors?

Who are Therapeutics Acquisition's key executives?

Therapeutics Acquisition's management team includes the following people:
  • Dr. Peter Kolchinsky Ph.D., Chairman & CEO (Age 44)
  • Dr. Matthew Hammond Ph.D., CFO, Chief Accounting Officer, Sec. & Director (Age 32)

What is Therapeutics Acquisition's stock symbol?

Therapeutics Acquisition trades on the NASDAQ under the ticker symbol "RACA."

How do I buy shares of Therapeutics Acquisition?

Shares of RACA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Therapeutics Acquisition's stock price today?

One share of RACA stock can currently be purchased for approximately $13.30.

How big of a company is Therapeutics Acquisition?

Therapeutics Acquisition has a market capitalization of $186.75 million.

What is Therapeutics Acquisition's official website?

The official website for Therapeutics Acquisition is www.researchalliancecorp.com.

How can I contact Therapeutics Acquisition?

Therapeutics Acquisition's mailing address is 200 BERKELEY STREET 18TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 617 778 2500.

This page was last updated on 1/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.